{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:18:56Z","timestamp":1768418336497,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.xphs.2024.09.011","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:03:05Z","timestamp":1727096585000},"page":"269-278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia"],"prefix":"10.1016","volume":"114","author":[{"given":"Jingjing","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunqi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzhen","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongping","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2024.09.011_bib0001","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00134-020-06151-x","article-title":"Incidence and mortality of hospital- and ICU-treated sepsis: results from an updated and expanded systematic review and meta-analysis","volume":"46","author":"Fleischmann-Struzek","year":"2020","journal-title":"Intensive Care Med"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0002","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12879-023-08209-9","article-title":"Efficacy, safety, and tolerability of antimicrobial agents for complicated intra-abdominal infection: a systematic review and network meta-analysis","volume":"23","author":"Kong","year":"2023","journal-title":"BMC Infect Dis"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.011_bib0003","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmi.2020.11.032","article-title":"Does dose reduction of renally cleared antibiotics in patients with impaired renal function lead to adequate drug exposure? A systematic review","volume":"27","author":"de Vroom","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.xphs.2024.09.011_bib0004","first-page":"1","article-title":"Pharmacokinetic alterations associated with critical illness","author":"Morales Castro","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.011_bib0006","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ijantimicag.2016.12.022","article-title":"Association between augmented renal clearance and clinical outcomes in patients receiving \u03b2-lactam antibiotic therapy by continuous or intermittent infusion: a nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial","volume":"49","author":"Udy","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0007","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s13054-021-03680-9","article-title":"Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis","volume":"25","author":"Pa\u0159\u00edzkov\u00e1","year":"2021","journal-title":"Crit Care"},{"issue":"8","key":"10.1016\/j.xphs.2024.09.011_bib0008","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.011_bib0009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1086\/649554","article-title":"Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America","volume":"50","author":"Solomkin","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.011_bib0010","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.011_bib0011","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron. Clinical Practice."},{"issue":"5","key":"10.1016\/j.xphs.2024.09.011_bib0012","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","article-title":"Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine","volume":"47","author":"Chan Kwong","year":"2020","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.011_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00845-22","article-title":"Population pharmacokinetics\/pharmacodynamics and clinical outcomes of meropenem in critically ill patients","volume":"66","author":"Boonpeng","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"10.1016\/j.xphs.2024.09.011_bib0014","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1093\/jac\/dkx209","article-title":"Too much of a good thing: a retrospective study of \u03b2-lactam concentration-toxicity relationships","volume":"72","author":"Imani","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0015","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01312-22","article-title":"Evaluation of empirical dosing regimens for meropenem in intensive care unit patients using population pharmacokinetic modeling and target attainment analysis","volume":"67","author":"An","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.xphs.2024.09.011_bib0016","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00228-016-2053-x","article-title":"Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients","volume":"72","author":"Mattioli","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.011_bib0017","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.xphs.2022.01.015","article-title":"Population pharmacokinetics analysis and dosing simulations of meropenem in critically ill patients with pulmonary infection","volume":"111","author":"Lan","year":"2022","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.011_bib0018","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00228-016-2172-4","article-title":"Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function","volume":"73","author":"Usman","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2024.09.011_bib0019","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2147\/IDR.S343264","article-title":"Meropenem target attainment and population pharmacokinetics in critically ill septic patients with preserved or increased renal function","volume":"15","author":"Gijsen","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"4","key":"10.1016\/j.xphs.2024.09.011_bib0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijantimicag.2014.12.017","article-title":"Augmented renal clearance, low \u03b2-lactam concentrations and clinical outcomes in the critically ill: an observational prospective cohort study","volume":"45","author":"Huttner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.xphs.2024.09.011_bib0021","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1128\/AAC.04166-14","article-title":"Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units","volume":"59","author":"Jaruratanasirikul","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0022","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1128\/AAC.38.1.151","article-title":"Pharmacokinetics of meropenem in patients with intra-abdominal infections","volume":"38","author":"Bedikian","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.xphs.2024.09.011_bib0023","doi-asserted-by":"crossref","first-page":"619","DOI":"10.2165\/00003495-200060030-00010","article-title":"Meropenem: an updated review of its use in the management of intra-abdominal infections","volume":"60","author":"Lowe","year":"2000","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0024","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/sur.2011.046","article-title":"Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review","volume":"13","author":"Adnan","year":"2012","journal-title":"Surg Infect (Larchmt)"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2024.09.011_bib0025","doi-asserted-by":"crossref","first-page":"S272","DOI":"10.1093\/infdis\/jiz651","article-title":"Association between pathophysiology and volume of distribution among patients with sepsis or septic shock treated with imipenem: a prospective cohort study","volume":"221","author":"Huang","year":"2020","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0026","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40121-021-00551-2","article-title":"Does prolonged infusion time really improve the efficacy of meropenem therapy? A prospective study in critically ill patients","volume":"11","author":"Zhao","year":"2022","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0027","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/jac\/dkp139","article-title":"Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution","volume":"64","author":"Roberts","year":"2009","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13017-024-00552-9","article-title":"Intra-abdominal infections survival guide: a position statement by the Global Alliance For Infections In Surgery","volume":"19","author":"Sartelli","year":"2024","journal-title":"World J Emerg Surg"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.011_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13111861","article-title":"Population pharmacokinetics of meropenem in critically ill korean patients and effects of extracorporeal membrane oxygenation","volume":"13","author":"Lee","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.xphs.2024.09.011_bib0030","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/FTD.0000000000000054","article-title":"Stability of generic meropenem solutions for administration by continuous infusion at normal and elevated temperatures","volume":"36","author":"Franceschi","year":"2014","journal-title":"Ther Drug Monit"},{"issue":"11","key":"10.1016\/j.xphs.2024.09.011_bib0031","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0032","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13054-020-2763-4","article-title":"Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial","volume":"24","author":"Ben\u00edtez-Cano","year":"2020","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.xphs.2024.09.011_bib0033","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2021.07.015","article-title":"Plasma and ascites pharmacokinetics of meropenem in patients with decompensated cirrhosis and spontaneous bacterial peritonitis","volume":"76","author":"Griemsmann","year":"2022","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.xphs.2024.09.011_bib0034","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jama.2023.10598","article-title":"Continuous vs intermittent meropenem administration in critically ill patients with sepsis: the MERCY randomized clinical trial","volume":"330","author":"Monti","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.xphs.2024.09.011_bib0035","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1001\/jama.2023.17733","article-title":"Meropenem administration in critically ill patients with sepsis","volume":"330","author":"Jabareen","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004209?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354924004209?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T01:35:45Z","timestamp":1734744945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354924004209"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022354924004209"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.011","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population pharmacokinetics and dosing simulations of meropenem in septic critically ill patients with complicated intra-abdominal infection or pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2024.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}